AI Insight
Researchers have discovered that semaglutide, the active ingredient in weight-loss medications Ozempic and Wegovy, appears to slow biological aging markers in adults living with HIV. This represents the first clinical evidence suggesting the drug may influence human aging processes. However, scientists emphasize that larger, more comprehensive studies are necessary before drawing definitive conclusions about the medication's anti-aging effects.
Why it matters
If confirmed in larger trials, these findings could expand the therapeutic applications of semaglutide beyond weight loss and diabetes management to potentially address age-related health decline. This discovery may open new avenues for developing interventions that target the biological mechanisms of aging.
Understand the Science
Researchers found that semaglutide, the active ingredient in Ozempic and Wegovy, slowed biological aging markers in adults with HIV, marking the first clinical evidence that the drug may influence human aging. Although the findings are encouraging, scientists say larger studies are needed before concluding that the medication can help people age more slowly.
Source: Popular weight-loss drugs Ozempic and Wegovy may slow biological aging